Tehran Aliyeva

Dr. Tehran Aliyeva


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2026 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
HMHatice Betigul Meral
Hatice Betigul Meral
TATehran Aliyeva
Tehran Aliyeva
ZOZeynep Meral Obholzer
Zeynep Meral Obholzer
EKErkan Kolak
Erkan Kolak
Fibromyalgia (FM) is a multifactorial syndrome involving central sensitization and psychosocial factors such as fear of movement and emotional distress. Ty

14 August 2025 in Toxins
Verified
Journal Article
Open access
PDF file
TATehran Aliyeva
Tehran Aliyeva
MOMehmet Fevzi Oztekin
Mehmet Fevzi Oztekin
YEYasemin Eren
Yasemin Eren
ZOZeynep Nese Oztekin
Zeynep Nese Oztekin
Hemifacial spasm (HFS) is a cranial nerve disorder characterized by involuntary contractions of muscles innervated by the facial nerve. Botulinum toxin type A (BoNT-A) is widely used for symptom control. Although local diffusion is well established, the extent and clinical relevance of BoNT-A spread to contralateral muscles remain unclear. This study aimed to investigate the contralateral neuromuscular effects of BoNT-A in patients undergoing long-term treatment with BoNT-A. This retrospective cross-sectional study included 39 patients with HFS (mean age, 58.6 ± 8.5 years). Bilateral compound muscle action potentials (CMAPs) were recorded before and four weeks after the BoNT-A injection. Single-fiber electromyography (SFEMG) jitter and mean consecutive difference (MCD) were evaluated contralaterally using concentric needle electrodes. Patients were categorized as first-time (n = 10) or long-term (n = 29; treatment duration: 1–20 years) BoNT-A recipients. Contralateral CMAP amplitudes decreased by 21.1% post-injection (p < 0.001). MCD increased from 33.2 ± 5.6 to 37.0 ± 5.3 µs (p < 0.001), and jitter rose by 81%, from 7.9 ± 6.2 to 14.3 ± 8.1 µs (p < 0.001). The percentage increase in MCD was significantly higher in long-term versus first-time patients (12.7% vs. 7.5%; p = 0.039), suggesting a cumulative neuromuscular effect. Spontaneous myokymia or fasciculations were clinically observed in four long-term patients. These findings provide electrophysiological evidence that unilateral BoNT-A injections may induce neuromuscular transmission abnormalities in the contralateral facial muscles. This effect appears more pronounced in chronically treated individuals, highlighting the need for awareness of potential bilateral spread when planning long-term therapy.

1 January 2026 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
HMHatice Betigul Meral
Hatice Betigul Meral
FAFikret Aysal
Fikret Aysal
TATehran Aliyeva
Tehran Aliyeva
ETEren Toplutaş
Eren Toplutaş
SUMMARY OBJECTIVE: The aim of this study was to investigate knowledge and health beliefs regarding osteoporosis in individuals with myasthenia gravis. METHODS: This cross-sectional study included 40 individuals with myasthenia gravis and 40 healthy controls, who were selected among individuals accompanying patients at outpatient clinics and hospital support staff. Participants completed the Revised Osteoporosis Knowledge Test and the Osteoporosis Health Belief Scale. For individuals with myasthenia gravis, additional data were collected, including disease duration, current use of prednisolone, and clinical classification. RESULTS: In the myasthenia gravis group, the mean total Revised Osteoporosis Knowledge Test score was 16.6±2.3, and the mean total Osteoporosis Health Belief Scale score was 146.4±6.1, with no statistically significant difference compared with the controls (p>0.05). The myasthenia gravis group had significantly higher "barriers to exercise" scores compared with controls (p<0.001). Only 37.5% of individuals with myasthenia gravis perceived themselves to be at risk of developing osteoporosis. In the patient group, educational level showed a strong positive correlation with both total Revised Osteoporosis Knowledge Test (r=0.756, p0.05). CONCLUSION: This study indicates that individuals with myasthenia gravis have inadequate knowledge and low perception of osteoporosis risk. To enhance early identification and prevent osteoporosis-related complications, implementing targeted educational and preventive strategies is essential in this vulnerable population.

18 July 2026 in Epilepsia Open
Verified
Journal Article
Open access
PDF file
TATehran Aliyeva
Tehran Aliyeva
FTFadime Çadırcı Tungaç
Fadime Çadırcı Tungaç
BTBeyza Tagraf
Beyza Tagraf
ÇOÇigdem Ozkara
Çigdem Ozkara
MUMustafa Uzan
Mustafa Uzan
LHLutfu Hanoglu
Lutfu Hanoglu
Objective: This study aimed to assess long‐term memory outcomes in patients with temporal lobe epilepsy ( TLE ) who underwent anterior temporal lobectomy ( ATL ) or selective amygdalohippocampectomy ( SAH ), compared to nonoperated TLE over a 10‐year follow‐up period. Methods: A total of 48 participants were studied: 10 ATL , 26 SAH , and 12 patients with nonoperated mesial temporal lobe epilepsy ( MTLE ). Verbal memory was assessed using the Sözel Bellek Süreçleri Testi ( SBST —a test of verbal memory processes), and nonverbal memory was evaluated with the Wechsler memory scale—visual reproduction ( WMS ) (Turkish adaptation). Given the small and unbalanced groups, linear mixed‐effects models ( LMMs ) were used as the primary inferential analyses to test group × time interactions. Statistically reliable individual changes were identified using the reliable change index ( RCI ). Neuropsychological outcomes were analyzed longitudinally over a 10‐year follow‐up period. Results: A significant group × time interaction was observed for verbal total learning ( p = 0.001). The nonoperated TLE group showed a significant decline over time, whereas both surgical groups differed significantly from it. The ATL group demonstrated significant improvement. For delayed verbal recall, a significant main effect of group was observed; however, the group × time interaction was not statistically significant. Visual immediate recall showed a significant group × time interaction ( p = 0.004), with a significant interaction effect in the ATL group. Visual delayed recall demonstrated a significant group × time interaction ( p < 0.001), with significant interaction effects in both surgical groups. Seizure freedom was achieved in 90% of ATL and 80% of SAH cases; however, seizure outcome was not significantly associated with memory outcomes. Reliable change index analyses indicated lateralization‐dependent patterns of change. Significance: ATL, particularly left‐sided ATL, was associated with statistically significant long‐term improvements in verbal memory and significant longitudinal changes in visual memory. SAH demonstrated significant longitudinal effects in selected memory domains. In contrast, nonoperated TLE patients showed significant cognitive decline over time. These findings highlight differential long‐term cognitive trajectories across treatment approaches and the role of lateralization in memory outcomes following epilepsy surgery. Plain Language Summary: We examined memory changes over 10 years in people with temporal lobe epilepsy who underwent different surgical treatments or received medical management alone. Patients who underwent anterior temporal lobectomy ( ATL ), particularly on the left side, showed improvement in certain memory measures over time. Those who had selective amygdalohippocampectomy ( SAH ) demonstrated more domain‐specific cognitive changes despite good seizure control. In contrast, patients who did not undergo surgery experienced a decline in verbal learning. These findings suggest that surgical approach and brain lateralization play important roles in long‐term memory outcomes.

7 August 2025 in Journal of Health Systems and Policies
Verified
Journal Article
Open access
PDF file
LHLütfü Hanoğlu
Lütfü Hanoğlu
DEDeniz Eruçar
Deniz Eruçar
TATehran Aliyeva
Tehran Aliyeva
BTBeyza Tağraf
Beyza Tağraf
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide. Recent advances in biomarker-based diagnostics and disease-modifying therapies have shifted the landscape of AD from symptom management to early intervention. This review examines current therapeutic innovations, with a particular focus on monoclonal antibodies such as lecanemab, aducanumab, and donanemab. While these agents show potential in slowing disease progression by targeting amyloid-beta accumulation, concerns remain regarding their clinical efficacy, safety profiles, and cost-effectiveness—especially in aging populations with high healthcare burdens. Additionally, developments in biological diagnosis through fluid and imaging biomarkers have introduced new ethical and policy-related challenges. The paper also highlights the role of non-pharmacological interventions, such as multidomain lifestyle programs, in enhancing cognitive reserve and delaying disease onset. Finally, the article calls for a comprehensive public health approach that includes precision medicine, national screening strategies, and policy reforms to address the growing societal impact of Alzheimer’s disease.

3 August 2026 in Acta Neurologica Belgica
Verified
Journal Article
Closed access
PDF file
AEAbdulkadir Ermiş
Abdulkadir Ermiş
TATehran Aliyeva
Tehran Aliyeva
ASAli Behram Salar
Ali Behram Salar
MAMelih Akan
Melih Akan
UÇUğur Çekmez
Uğur Çekmez
EBErkingül Birday
Erkingül Birday